Epoch Investment Partners Inc. boosted its position in Zoetis Inc (NYSE:ZTS) by 102.3% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 59,445 shares of the company’s stock after acquiring an additional 30,067 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Zoetis were worth $5,085,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Berman Capital Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth about $26,000. Athena Capital Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter worth about $29,000. Resources Investment Advisors Inc. bought a new stake in shares of Zoetis in the 4th quarter worth about $31,000. Lavaca Capital LLC bought a new stake in shares of Zoetis in the 4th quarter worth about $32,000. Finally, Acima Private Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter worth about $34,000. 89.98% of the stock is owned by institutional investors.
In other Zoetis news, insider Catherine A. Knupp sold 32,767 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $95.80, for a total value of $3,139,078.60. Following the completion of the transaction, the insider now owns 82,820 shares in the company, valued at approximately $7,934,156. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Clinton A. Jr. Lewis sold 6,125 shares of the company’s stock in a transaction dated Monday, January 14th. The stock was sold at an average price of $85.21, for a total transaction of $521,911.25. Following the completion of the transaction, the insider now owns 48,070 shares of the company’s stock, valued at approximately $4,096,044.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 406,209 shares of company stock valued at $38,120,373. 0.35% of the stock is owned by insiders.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 14th. The company reported $0.79 earnings per share for the quarter, beating analysts’ consensus estimates of $0.77 by $0.02. Zoetis had a net margin of 24.51% and a return on equity of 73.85%. The business had revenue of $1.56 billion during the quarter, compared to the consensus estimate of $1.53 billion. During the same quarter in the prior year, the firm earned $0.69 EPS. The company’s revenue for the quarter was up 7.1% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc will post 3.46 earnings per share for the current fiscal year.
Zoetis declared that its board has approved a stock repurchase program on Wednesday, December 12th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the company to reacquire up to 4.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s management believes its shares are undervalued.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be given a $0.164 dividend. This represents a $0.66 annualized dividend and a yield of 0.68%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio (DPR) is 21.09%.
ZTS has been the subject of several research analyst reports. Stifel Nicolaus raised shares of Zoetis from a “hold” rating to a “buy” rating and boosted their target price for the stock from $97.00 to $110.00 in a research report on Monday, March 4th. Zacks Investment Research raised shares of Zoetis from a “sell” rating to a “hold” rating in a research report on Saturday, February 16th. BMO Capital Markets boosted their target price on shares of Zoetis from $93.00 to $101.00 and gave the stock a “market perform” rating in a research report on Monday, February 25th. Finally, UBS Group initiated coverage on shares of Zoetis in a research report on Wednesday, January 23rd. They set a “neutral” rating and a $86.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $98.85.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
See Also: Index Funds
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.